{"organizations": [], "uuid": "4423afff0f6ad73c5f26aefae069f16235fbe2f5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/05/globe-newswire-obalon-announces-fourth-quarter-and-full-year-2017-financial-results.html", "country": "US", "domain_rank": 767, "title": "Obalon Announces Fourth Quarter and Full Year 2017 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.097, "site_type": "news", "published": "2018-03-05T23:01:00.000+02:00", "replies_count": 0, "uuid": "4423afff0f6ad73c5f26aefae069f16235fbe2f5"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/05/globe-newswire-obalon-announces-fourth-quarter-and-full-year-2017-financial-results.html", "ord_in_thread": 0, "title": "Obalon Announces Fourth Quarter and Full Year 2017 Financial Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "new u.s.", "sentiment": "none"}], "organizations": [{"name": "obalon therapeutics, inc.", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial results as of and for the fourth quarter and full year ended December 31, 2017.\nFourth Quarter highlights:\nQ4-17 total revenue of $3.7 million grew 32% sequentially over Q3-17 Q4-17 U.S. revenue of $2.9 million grew 43% sequentially over Q3-17 Highest number of new U.S. accounts sold of any quarter since U.S. launch U.S. reorder revenue exceeds revenue from new account additions for first quarter since U.S. launch Gross margin improved to 54%\nFull Year 2017 highlights:\nFull year 2017 revenue increased 192% year over year to $9.9 million Full year U.S. revenue of $8.3 million for first year of U.S. commercialization New U.S. account revenue accounted for approximately 60% and U.S. reorder revenue accounted for approximately 40% of total U.S. revenue\nFourth Quarter 2017 Results:\nThe Company reported total revenue of $3.7 million for the fourth quarter of 2017, compared to $0.8 million for the fourth quarter of 2016. U.S. revenue of $2.9 million represented 78% of total revenue and international revenue of $0.8 million represented 22% of total revenue for the fourth quarter 2017.\nNet loss was reported at $10.1 million compared to a net loss of $7.5 million in the fourth quarter of 2016 and net loss per share was $0.60 for the fourth quarter of 2017 as compared to net loss per share of $0.51 for the fourth quarter of 2016.\nCost of goods sold was $1.7 million during the three months ended December 31, 2017, up from $0.9 million for the prior year period. Gross profit for the fourth quarter of 2017 was $2.0 million, resulting in a gross margin of 54%, compared to a gross loss of $0.1 million and gross margin of -13% for the fourth quarter of 2016.\nResearch and Development expense for the fourth quarter of 2017 totaled $2.7 million, up from $2.6 million in the fourth quarter of 2016, and Selling, General and Administrative expense increased to $9.2 million for the fourth quarter of 2017, compared to $4.8 million in the fourth quarter 2016.\nOperating loss for the fourth quarter of 2017 was $9.9 million, compared to an operating loss of $7.5 million for the fourth quarter of 2016.\nAs of December 31, 2017, cash, cash equivalents and short-term investments were $44.4 million and total debt was $10.0 million.\nFull Year 2017 Results\nObalon reported full year 2017 total revenue of $9.9 million, a 192% increase from $3.4 million for the full year 2016. U.S. revenue of $8.3 million represented 83% of full year 2017 revenue. International revenue of $1.7 million equated to 17% of full year revenue as compared to 100% of full year revenue in 2016.\nGross profit for the full year 2017 was $5.1 million, a gross margin of 51%, and increased from a gross profit of $0.6 million in the prior year and a gross margin of 17%.\nResearch and Development expense totaled $10.7 million for the full year 2017, up from $9.9 million for the full year 2016, and Selling, General and Administrative expense increased to $28.8 million for the full year 2017, compared to $10.2 million for the full year 2016.\nOperating loss for the full year 2017 was $34.4 million, compared to an operating loss of $19.5 million for the full year 2016.\nNet loss was reported at $34.8 million for the full year 2017 compared to a net loss of $20.5 million for the full year 2016 and net loss per share was $2.08 for the full year 2017 as compared to net loss per share of $4.85 for the full year 2016.\nCall Information\nA conference call to discuss fourth quarter 2017 financial results is scheduled for today, March 5, 2018, at 5:00 PM Eastern Standard Time (2:00 PM Pacific Standard Time). Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 1178907. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m6/p/sfqrxtdj .\nAn archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics, Inc. website located at http://investor.obalon.com in the “News & Events” section.\nAbout Obalon Therapeutics, Inc.\nObalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com .\nFor Obalon Therapeutics, Inc.\nInvestor Contact:\nWilliam Plovanic\nChief Financial Officer\nObalon Therapeutics, Inc.\nOffice: +1 760 607 5103\nwplovanic@obalon.com\nMedia:\nMegan Driscoll\nEvolveMKD\nOffice Phone: +1 646 517 4220\nmdriscoll@evolvemkd.com\nOBALON THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except shares and per share data) Three months ended December 31, Year ended December 31, 2017 2016\n2017 2016 Revenue: Revenue $ 3,692 — $ 9,914 $ — Revenue, related party — 772 — 3,393 Total revenue 3,692 772 9,914 3,393 Cost of revenue 1,702 871 4,829 2,809 Gross profit 1,990 (99 ) 5,085 584 Operating expenses: Research and development 2,689 2,605 10,647 9,872 Selling, general and administrative 9,223 4,830 28,829 10,217 Total operating expenses 11,912 7,435 39,476 20,089 Loss from operations (9,922 ) (7,534 ) (34,391 ) (19,505 ) Interest expense, net (25 ) (52 ) (135 ) (477 ) Gain (loss) from change in fair value of warrant liability — 84 — (466 ) Other (expense) income, net (173 ) 7 (239 ) (19 ) Net loss (10,120 ) (7,495 ) (34,765 ) (20,467 ) Other comprehensive loss income — (6 ) (4 ) (1 ) Net loss and comprehensive loss $ (10,120 ) $ (7,501 ) $ (34,769 ) $ (20,468 ) Net loss per share, basic and diluted $ (0.60 ) $ (0.51 ) $ (2.08 ) $ (4.85 ) Weighted-average common shares outstanding, basic and diluted 16,918,702 14,689,828 16,717,106 4,221,893\nOBALON THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except shares and par value data) December 31, 2017 2016 Assets Current assets: Cash and cash equivalents $ 21,108 $ 72,975 Short-term investments 23,292 2,500 Accounts receivable, net 4,223 — Accounts receivable, related party — 515 Inventory 1,418 827 Other current assets 1,714 1,244 Total current assets 51,755 78,061 Property and equipment, net 1,346 717 Total assets $ 53,101 $ 78,778 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 1,276 $ 595 Accrued compensation 4,494 2,497 Deferred revenue 510 121 Other current liabilities 1,773 1,379 Current portion of long-term loan 1,958 — Total current liabilities 10,011 4,592 Deferred rent 13 — Long-term loan, excluding current potion 7,964 9,881 Total long-term liabilities 7,977 9,881 Total liabilities 17,988 14,473 Commitments and contingencies Stockholders’ equity: Common stock, $0.001 par value; 300,000,000 shares authorized at December 31, 2017 and December 31, 2016; 17,500,604 and 16,773,205 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively 18 17 Additional paid-in capital 146,474 140,898 Accumulated other comprehensive loss (5 ) (1 ) Accumulated deficit (111,374 ) (76,609 ) Total stockholders’ equity 35,113 64,305 Total liabilities and stockholders’ equity $ 53,101 $ 78,778\nOBALON THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) 2017 2016 Operating activities: Net loss $ (34,765 ) $ (20,467 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 330 192 Stock-based compensation 3,241 563 Fair value of stock issued for legal settlements 1,606 — Loss on disposal of fixed assets — 13 Change in fair value of warrant liability — 466 Amortization of investment premium, net 18 125 Amortization of debt discount 42 70 Change in operating assets and liabilities: Accounts receivable, net (4,223 ) — Accounts receivable from related party 515 121 Inventory (591 ) (464 ) Other current assets (470 ) (985 ) Accounts payable 624 46 Accrued compensation 1,997 1,247 Deferred revenue 389 121 Other current and long-term liabilities 663 (416 ) Net cash used in operating activities (30,624 ) (19,368 ) Investing activities: Purchases of short-term investments (94,613 ) (18,897 ) Maturities of short-term investments 73,800 25,450 Purchase of property and equipment (1,043 ) (352 ) Net cash (used in) provided by investing activities (21,856 ) 6,201 Financing activities: Issuance of preferred stock for cash, net of offering costs — 14,517 Proceeds from initial public offering, net of issuance costs — 67,233 Proceeds from long-term loan, net of issuance costs — — Fees paid in connection with loan amendment — (30 ) Proceeds from common stock issued under employee stock purchase plan 429 — Proceeds from sale of common stock upon exercise of stock options 184 1,066\nNet cash provided by financing activities 613 82,786\nEffect of exchange rate changes on cash and cash equivalents — — Net (decrease) increase in cash and cash equivalents (51,867 ) 69,619 Cash and cash equivalents at beginning of period 72,975 3,356 Cash and cash equivalents at end of period $ 21,108 $ 72,975 Supplemental cash flow information: Interest paid $ 562 $ 527 Income taxes paid $ 2 $ — Conversion of convertible preferred stock to common stock $ — $ 70,498 Net exercises of warrants $ — $ 591 Conversion of customer deposit from related party to preferred stock $ — $ 1,283 Property and equipment in accounts payable $ 83 $ 140\nSource:Obalon Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=hz5sqsGzd3D2TpxPRsYN_hrOZWK5WCuKcnfaL0OkEn7yGIuliRsQTODqMU62JRTShFj8btAuENMftFjkx_-ykhfszzkAV-nMRULIzs9kI3Y-98HN2ljGtqkt4FGiu3UlRE0dFYRMXJFgVhRFlDpAx5KTP84AfyCxv3g9bDKRk2ckJaNs0y4lU5zkRa74gURA7VhKQ3PG1xOHSEyJ87JoQfrhSDfKDjEqRrVgxd5oMGwMpPW4b0kO2X8ZomjaDIj1j1Cw4RntqVWIZB4G8-5Kqw==", "https://www.globenewswire.com/Tracker?data=8LJxV9utK9grkQDWmw1X72JU9vME6uivKel3a6u9iHhhKpS84Rpu1lb20mKrttvx3Wj3NWqHEsDWWk6fp4AOrZjtXlOQi4YzQfLZ8s7rakItzo6erhv2Fay323dNwHe4rajHkajkTPMY4QCrGfQW-SBlwz2C02NlHmQx9VdbXGMVwJScQ--GFl9yIPnmnMdx9KQrhYazaiEDQUx6QserqRpLNFzeM9FKpgSxyImSbVs_mBGl4vHTFmKPk2ikbb7GldCaX9BbouWLpjH_X7Ejtw==", "https://www.globenewswire.com/Tracker?data=K5VlHgpEXdzsZwG0dL-1Qdv9x3UO9_j7BAjnYcNIWddfWhOQXaS-9o0Jk_HCM9eD_nQ9BFHYPvdZo512A0ri2g==", "https://www.globenewswire.com/Tracker?data=hz5sqsGzd3D2TpxPRsYN_iPaPvT5ZVsH8YLBj3RcE3dzMZEVtLYapyy_iCaiJfnq7YRUw4tr-9uiOtQqlcrWBSdZazj4CAhtznohNHAUb8k5xQJuAnp6AKVOy3DqWfDuaKwgX40Wvml0zA3D5b36zw==", "http://edge.media-server.com/m6/p/sfqrxtdj", "https://www.globenewswire.com/NewsRoom/AttachmentNg/e02ca260-1349-45d0-a97e-755cdb8403b4", "https://www.globenewswire.com/Tracker?data=J6hFWrZJVHrUgxnw6ZYu3id_xaeuZ9cLzFYwSUd3ohhvXb1kELFcIyX4HwLlK7p47je43yVKpxquhnx2p_6osxdSIVXPYabzbgN2B4AocoKsnwY59LvH7-mK1HeCWgpqrbhEOivAx0M05BnlsrcLNAMoh-q1eWMiTftj8IptKmjtuV3c8HgigFHs6hnlGX_9AXu8zII68t-65iyO8l8sxFCuniDyNAIHoC0O0LEEnwJAIQKl0IFku3Zz-GeY1PCEVn1_xczumFTW-56Z8Xcpzg=="], "published": "2018-03-05T23:01:00.000+02:00", "crawled": "2018-03-06T00:39:56.009+02:00", "highlightTitle": ""}